MedTrace Logo

Atrial Fibrillation in Patients Receiving Ibrutinib

NCT04407845 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-06-09

No results posted yet for this study

Summary

Ibrutinib (a tyrosine kinase inhibitor targeting Bruton) is a standard of treatment in haematology. According to retrospective data, atrial fibrillation and systemic hypertension are common ibrutinib-related advserse events. The investigators aim at prospectively establishing the incidence of thesedrug related advsere events through clinical monitoring and attempt at identifying populations at risk.

Conditions

Sponsors & Collaborators

  • European Georges Pompidou Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-21
Primary Completion
2022-05-21
Completion
2022-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407845 on ClinicalTrials.gov